Litcius/Paper detail

FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation

Jun Hu, Xing Liu, Shiyu Xia, Zhibin Zhang, Ying Zhang, Jingxia Zhao, Jianbin Ruan, Xuemei Luo, Xiwen Lou, Yang Bai, Junhong Wang, Louis Hollingsworth, Venkat Giri Magupalli, Li Zhao, Hongbo R. Luo, Justin Kim, Judy Lieberman, Hao Wu

2020Nature Immunology1,100 citationsDOIOpen Access PDF

Topics & Concepts

PyroptosisDisulfiramInflammationProgrammed cell deathCytokine stormInflammasomeApoptosisPharmacologyChemistryCaspaseProinflammatory cytokineMedicineImmunologyBiochemistryCoronavirus disease 2019 (COVID-19)DiseaseInfectious disease (medical specialty)PathologyInflammasome and immune disordersHeme Oxygenase-1 and Carbon MonoxideGout, Hyperuricemia, Uric Acid
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation | Litcius